Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$38000.0.

  • Cartesian Therapeutics' Cash from Financing Activities fell 10003.05% to -$38000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.2 million, marking a year-over-year decrease of 10397.3%. This contributed to the annual value of $168.4 million for FY2024, which is 138130.85% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Cash from Financing Activities stood at -$38000.0 for Q3 2025, which was down 10003.05% from $60000.0 recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Cash from Financing Activities high stood at $124.5 million for Q3 2024, and its period low was -$24.8 million during Q3 2023.
  • For the 5-year period, Cartesian Therapeutics' Cash from Financing Activities averaged around $13.3 million, with its median value being $1.1 million (2021).
  • As far as peak fluctuations go, Cartesian Therapeutics' Cash from Financing Activities crashed by 415049.02% in 2023, and later skyrocketed by 2877986.58% in 2024.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Cash from Financing Activities stood at $21.2 million in 2021, then tumbled by 97.11% to $612000.0 in 2022, then surged by 2200.82% to $14.1 million in 2023, then tumbled by 94.44% to $783000.0 in 2024, then plummeted by 104.85% to -$38000.0 in 2025.
  • Its Cash from Financing Activities stands at -$38000.0 for Q3 2025, versus $60000.0 for Q2 2025 and -$8.0 million for Q1 2025.